Principal Scientist/Sr. Principal Scientist, CMC, Analytical Chemistry

Principal Scientist/Sr. Principal Scientist, CMC, Analytical Chemistry Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting, and continue to advance an early-stage pipeline of novel therapeutic candidates. In 2025, we initiated Phase 1 trials for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7). Nav1.7 and Kv7 are important pain targets, and data from these Phase 1 studies are expected in 2026 to support Phase 2 proof-of-concept studies in acute pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. About the Role: We are seeking a Principal/Senior Principal Scientist, CMC, Analytical Chemistry to join our team. This position will report to the Executive Director, CMC, Analytical Development and will be responsible for the development of analytical methodology and characterization activities in support of new drug substance and new drug product development and manufacturing. He/she will provide analytical support for API and drug product manufacture in support of preclinical and clinical batches. This position will be based out of Vancouver, BC, Canada. The level of the position will be commensurate with the candidate’s education and industry experience. Relocation and immigration support will be provided, if required. Hybrid positions require a minimum of two onsite days per week. On-site positions require up to five on-site days per week. RESPONSIBILITIES: - Lead a team of scientists and research associates supporting the development of New Chemical Entities drug substance and drug product for preclinical and clinical programs within the CMC group in close collaboration with the CMC teams. - Collaborate with colleagues in Discovery to transfer product candidates into the CMC group. - Identify and recommend analytical methodologies to support chemical development, formulation development, QC, and stability testing. Lead and perform activities related to analytical method development, optimization, troubleshooting, qualification, validation, and transfer activities for starting materials, process intermediates, drug substances, drug products, internally and at CMOs. - Work with multi-functional project teams to design and execute phase-appropriate ... (truncated, view full listing at source)